PharmiGene Gets OK to Market PGx Test for Carbamazepine Patients in Taiwan | GenomeWeb
NEW YORK (GenomeWeb News) – PharmiGene said today that the Department of Health in Taiwan has granted the firm approval to market its PG 1502 DNA detection kit on the island.
 
The test is used to identify patients at greater risk for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis, which are life-threatening adverse drug reactions. Carbamazepine is an anti-convulsant and mood-stabilizing drug used to treat epilepsy, biopolar disorder, and schizophrenia, among other conditions.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.